Re: anti cd 19 BiTne

[Guest guest]

I am in the middle of blogging about it.

Terry Hamblin

http://mutated-unmuated.blogspot.com/

In a message dated 21/06/2011 aramezk writes:

Can someone enlighten me on the success of this

new approach to fighting cll?

[Guest guest]

This is not really new...there was a German study using this

BiTE technology in CLL cells in 2002 with MT103...now called

Blinatumomab.(MEDI-538)

It is currently in Phase I clinical trials for NHL and ALL.

The findings were presented on June 12, 2010 in an oral

presentation (abstract # 0559) at the 15th Annual Congress

of the European Hematology Association (EHA) in Barcelona,

Spain.

" Blinatumomab continues to demonstrate a long duration of

response in heavily pre-treated non-Hodgkin's lymphoma

patients, " said Professor Ralph Bargou, Division of

Hematology and Oncology, Department of Internal Medicine II,

Wuerzburg University Hospital, and the study's principal

investigator.

" Results of the expanded Phase 1 experience suggest that

blinatumomab has the potential to alter the clinical course

of disease in patients with a variety of NHL sub-types. "

Of the 52 patients most had follicular lymphoma (FL) (42%)

and mantle cell lymphoma (MCL) (42%). The median response

was 21 months, but only 8 of the 52 patients were evaluated,

no idea why the number was so small...perhaps it has to do

with dosage.

Perhaps CLL trials will follow...but nothing has been

announced, to my knowledge.

More Here:

http://www.medicalnewstoday.com/releases/194344.php

Current Clinical Trials: http://clinicaltrials.gov/ct2/results?term=MT103

ASH 2007: http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_2863